Martin Gunnarsson

4.1k total citations · 2 hit papers
47 papers, 2.1k citations indexed

About

Martin Gunnarsson is a scholar working on Pathology and Forensic Medicine, Oncology and Neurology. According to data from OpenAlex, Martin Gunnarsson has authored 47 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pathology and Forensic Medicine, 14 papers in Oncology and 12 papers in Neurology. Recurrent topics in Martin Gunnarsson's work include Multiple Sclerosis Research Studies (34 papers), Polyomavirus and related diseases (13 papers) and Peripheral Neuropathies and Disorders (9 papers). Martin Gunnarsson is often cited by papers focused on Multiple Sclerosis Research Studies (34 papers), Polyomavirus and related diseases (13 papers) and Peripheral Neuropathies and Disorders (9 papers). Martin Gunnarsson collaborates with scholars based in Sweden, United Kingdom and United States. Martin Gunnarsson's co-authors include Anders Svenningsson, Peter Sundström, Jan Lycke, Fredrik Piehl, Tomas Olsson, Magnus Vrethem, Clas Malmeström, Markus Axelsson, Niklas Norgren and Lars Rosengren and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Neurology.

In The Last Decade

Martin Gunnarsson

46 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

2019 346 citations Peter Alping, Joachim Burman et al. profile →
Monitoring disease activity in multiple sclerosis using serum neurofilament light protein

2017 325 citations Henrik Zetterberg, Peter Sundström et al. Neurology profile →

Peers

Countries citing papers authored by Martin Gunnarsson

Since Specialization

Citations

This map shows the geographic impact of Martin Gunnarsson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Gunnarsson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Gunnarsson more than expected).

Fields of papers citing papers by Martin Gunnarsson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Gunnarsson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Gunnarsson. The network helps show where Martin Gunnarsson may publish in the future.

Co-authorship network of co-authors of Martin Gunnarsson

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Gunnarsson. A scholar is included among the top collaborators of Martin Gunnarsson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Gunnarsson. Martin Gunnarsson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Nicotine, Alcohol Consumption, and Risk of Myasthenia Gravis 2025 ·Neurology ·(unknown), Daniel Jons, Amalia Feresiadou, Andreea Ilinca, Fredrik Lundin, (unknown), (unknown), (unknown), (unknown), Martin Gunnarsson, Peter Sundström, Lars Klareskog, Tomas Olsson, Ingrid Kockum, Fredrik Piehl, Lars Alfredsson, Susanna Brauner	0
2	COMBAT‐MS: A Population‐Based Observational Cohort Study Addressing the Benefit–Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab 2024 ·Annals of Neurology ·Fredrik Piehl, Peter Alping, (unknown), Simon Englund, Joachim Burman, Katharina Fink, Anna Fogdell‐Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer‐Gould, (unknown), Johan Mellergård, Petra Nilsson, Tomas Olsson, Jonatan Salzer, Anders Svenningsson, Thomas Frisell	3
3	Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy 2023 ·Journal of Neurology Neurosurgery & Psychiatry ·Elisa Longinetti, Simon Englund, Joachim Burman, Katharina Fink, Anna Fogdell‐Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer‐Gould, Jan Lycke, Petra Nilsson, Jonatan Salzer, Anders Svenningsson, Johan Mellergård, Tomas Olsson, Fredrik Piehl, Thomas Frisell	7
4	Seroreactivity against lytic, latent and possible cross-reactive EBV antigens appears on average 10 years before MS induced preclinical neuroaxonal damage 2023 ·Journal of Neurology Neurosurgery & Psychiatry ·Daniel Jons, (unknown), Tomas Bergström, Henrik Zetterberg, Martin Biström, Martin Gunnarsson, Magnus Vrethem, Nicole Brenner, Julia Butt, Kaj Blennow, Staffan Nilsson, Ingrid Kockum, Tomas Olsson, Tim Waterboer, Peter Sundström, Oluf Andersen	9
5	Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohort 2022 ·Multiple Sclerosis and Related Disorders ·Simon Englund, Marie Kierkegaard, Joachim Burman, Katharina Fink, Anna Fogdell‐Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer‐Gould, Jan Lycke, Petra Nilsson, Jonatan Salzer, Anders Svenningsson, Johan Mellergård, Tomas Olsson, Elisa Longinetti, Thomas Frisell, Fredrik Piehl	9
6	Clinical effectiveness of dimethyl fumarate with focus on patients treated at least 36 months - a Swedish nationwide study of the long-term effectiveness and safety of dimethyl fumarate (IMSE5) 2019 ·Multiple Sclerosis Journal ·Lars Forsberg, (unknown), Anna Fält, Å. Berglund, Jan Hillert, Petra Nilsson, Charlotte Dahle, Anders Svenningsson, Jan Lycke, Anne‐Marie Landtblom, Joachim Burman, (unknown), Peter Sundström, Martin Gunnarsson, Fredrik Piehl, Tommy Olsson	1
7	High serum concentration of vitamin D may protect against multiple sclerosis 2019 ·Multiple Sclerosis Journal - Experimental Translational and Clinical ·Martin Biström, Lucía Alonso-Magdalena, Oluf Andersen, Daniel Jons, Martin Gunnarsson, Magnus Vrethem, Johan Hultdin, Peter Sundström	13
8	A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and effectiveness of dimethyl fumarate (IMSE 5) 2018 ·Multiple Sclerosis Journal ·(unknown), (unknown), Anna Fält, Å. Berglund, Jan Hillert, Per‐Gunnar Nilsson, Charlotte Dahle, Anders Svenningsson, Jan Lycke, Anne‐Marie Landtblom, Joachim Burman, Peter Sundström, (unknown), Martin Gunnarsson, Fredrik Piehl, Tommy Olsson	4
9	Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls 2018 ·PLoS ONE ·Pierre de Flon, Lars Söderström, Katarina Laurell, Ann Dring, Peter Sundström, Martin Gunnarsson, Anders Svenningsson	15
10	Conventional and synthetic MRI in multiple sclerosis: a comparative study 2017 ·European Radiology ·(unknown), Martin Gunnarsson, Margareta Nilsson, Per Thunberg	34
11	CoDuSe group exercise programme improves balance and reduces falls in people with multiple sclerosis: A multi-centre, randomized, controlled pilot study 2016 ·Multiple Sclerosis Journal ·(unknown), Anette Forsberg, Martin Gunnarsson, Ylva Nilsagård	52
12	Accuracy and reproducibility of a quantitative magnetic resonance imaging method for concurrent measurements of tissue relaxation times and proton density 2015 ·Magnetic Resonance Imaging ·(unknown), Martin Gunnarsson, Torbjörn Andersson, Per Thunberg	70
13	Correlation between maximal walking distance and self-rated limitations in walking 2014 ·Multiple Sclerosis Journal ·Ylva Nilsagård, Elisabeth Westerdahl, (unknown), Martin Gunnarsson	1
14	Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience 2014 ·Journal of Neurology Neurosurgery & Psychiatry ·Joachim Burman, Ellen Iacobaeus, Anders Svenningsson, Jan Lycke, Martin Gunnarsson, Petra Nilsson, Magnus Vrethem, S. Fredrikson, Claes Martin, Anna Sandstedt, Bertil Uggla, Stig Lenhoff, Jan‐Erik Johansson, Cecilia Isaksson, Hans Hägglund, Kristina Carlson, Jan Fagius	118
15	Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis 2013 ·Multiple Sclerosis Journal ·Markus Axelsson, Clas Malmeström, Martin Gunnarsson, Henrik Zetterberg, Peter Sundström, Jan Lycke, Anders Svenningsson	102
16	Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab 2010 ·Annals of Neurology ·Martin Gunnarsson, Clas Malmeström, Markus Axelsson, Peter Sundström, Charlotte Dahle, Magnus Vrethem, Tomas Olsson, Fredrik Piehl, Niklas Norgren, Lars Rosengren, Anders Svenningsson, Jan Lycke	262
17	Stimulation of peripheral blood mononuclear cells with lipopolysaccharide induces expression of the plasma protein α2-macroglobulin 2003 ·Protein Expression and Purification ·Martin Gunnarsson, Lars Frängsmyr, Torgny Stigbrand, Poul Erik Jensen	9
18	Decreased stability of alpha2-macroglobulin purified from patients with multiple sclerosis 2000 ·Acta Neurologica Scandinavica ·Martin Gunnarsson, Torgny Stigbrand, Poul Erik Jensen	5
19	Conformational variants of human α₂‐macroglobulin are reflected in a C‐terminal ‘switch region’ 2000 ·European Journal of Biochemistry ·Martin Gunnarsson, Torgny Stigbrand, Poul Erik Jensen	7
20	Aberrant forms of α2-macroglobulin purified from patients with multiple sclerosis 2000 ·Clinica Chimica Acta ·Martin Gunnarsson, Torgny Stigbrand, Poul Erik Jensen	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact